Syngene International has announced the conclusion of the acquisition of a multi-modal biologics manufacturing facility from Stelis Biopharma as announced on 4 July 2023.
The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs. 617 crore adjusted from the earlier gross value of Rs. 702 crore. The reduction in gross value reflects the retention of certain equipment not currently installed in the facility by Stelis Biopharma.
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. It also includes a commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing.
The Unit has been acquired effective 1st December, 2023 on payment of Rs. 395 crore. The balance, subject to final adjustments, will be paid in December 2023 on completion of certain post-closing actions by Stelis Biopharma.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!